Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas—A German Survey

• Published in: The journal of clinical endocrinology and metabolism Vol. 105; no. 3; pp. e660 - e675
• Main Authors: Elbelt, Ulf, Schlaffer, Sven M, Buchfelder, Michael, Knappe, Ulrich J, Vila, Greisa, Micko, Alexander, Deutschbein, Timo, Unger, Nicole, Lammert, Alexander, Topuzoglu-Müller, Tengü, Bojunga, Jörg, Droste, Michael, Johanssen, Sarah, Kolenda, Herbert, Ritzel, Katrin, Buslei, Rolf, Strasburger, Christian J, Petersenn, Stephan, Honegger, Jürgen
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.03.2020; Copyright Oxford University Press
• Subjects: Brain cancer; Brain tumors; Cancer; Carcinoma; Diagnosis; Patients; Pituitary; Pituitary gland; Survival; Temozolomide; Tumors; temozolomide; pituitary carcinoma; aggressive pituitary tumor; progression-free survival; response rate
• ISSN: 0021-972X; 1945-7197; 1945-7197
• DOI: 10.1210/clinem/dgz211

Abstract Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging. Objective We therefore aimed to report on clinical characteristics leading to initiation of TMZ therapy and to add evidence on TMZ long-term effectiveness. Design and subjects Retrospective survey on TMZ treatment in patients with APTs or PCs. TMZ therapy was initiated in 47 patients (22 females) with APTs (n = 34) or PCs (n = 13). Mean age at diagnosis was 45 ± 15 years. The immunohistochemical subtypes were corticotroph (n = 20), lactotroph (n = 18), and nonfunctioning (n = 9) tumors. TMZ therapy started 8 years after initial diagnosis using a standard regimen (median 6 cycles) for the majority of patients. Results Long-term radiological response to TMZ after a median follow-up of 32 months with 4 patients still on TMZ therapy was tumor regression for 9 (20%), stable disease for 8 (17%), and tumor progression for 29 patients (63%) (outcome data available for 46 patients). Progression occurred 16 months after initiation of TMZ. Median estimated progression-free survival was 23 months. Disease stabilization and median progression-free survival did not differ between patients with APTs or PCs. Predictors of tumor response were not identified. Overall, TMZ was well tolerated. Conclusion We performed a nationwide survey on TMZ therapy in patients with APTs and PCs. While early response rates to TMZ are promising, long-term outcome is less favorable. Prolonged TMZ administration should be considered. We were not able to confirm previously reported predictors of tumor response to TMZ.